CS208479B2 - Method of making the well compatible water solution for the intraveous administration - Google Patents

Method of making the well compatible water solution for the intraveous administration Download PDF

Info

Publication number: CS208479B2
Authority: CS; Czechoslovakia
Prior art keywords: solution; sugar; diamino; water; pyrimidine
Prior art date: 1977-07-08

Application number

CS784554A

Other languages

Czech (cs)

English (en)

Inventor

Karl Dr Groke

Original Assignee

Chemie Linz Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1977-07-08

Filing date

1978-07-07

Publication date

1981-09-15

1978-07-07 Application filed by Chemie Linz Ag filed Critical Chemie Linz Ag

1981-09-15 Publication of CS208479B2 publication Critical patent/CS208479B2/cs

Links

XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims description 20
238000004519 manufacturing process Methods 0.000 title description 2
239000000243 solution Substances 0.000 claims abstract description 53
239000007864 aqueous solution Substances 0.000 claims abstract description 12
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 11
239000008103 glucose Substances 0.000 claims abstract description 11
229930091371 Fructose Natural products 0.000 claims abstract description 10
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims abstract description 10
239000005715 Fructose Substances 0.000 claims abstract description 10
238000001990 intravenous administration Methods 0.000 claims abstract description 4
150000003839 salts Chemical class 0.000 claims abstract description 4
IZOYMGQQVNAMHS-UHFFFAOYSA-N sulfametrole Chemical compound COC1=NSN=C1NS(=O)(=O)C1=CC=C(N)C=C1 IZOYMGQQVNAMHS-UHFFFAOYSA-N 0.000 claims abstract description 4
150000005846 sugar alcohols Chemical class 0.000 claims abstract description 3
235000000346 sugar Nutrition 0.000 claims description 18
238000000034 method Methods 0.000 claims description 9
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 8
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
230000001476 alcoholic effect Effects 0.000 claims description 5
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 5
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 5
235000010447 xylitol Nutrition 0.000 claims description 5
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
229930195725 Mannitol Natural products 0.000 claims description 4
239000000594 mannitol Substances 0.000 claims description 4
235000010355 mannitol Nutrition 0.000 claims description 4
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
238000002360 preparation method Methods 0.000 claims description 3
239000000600 sorbitol Substances 0.000 claims description 3
235000010356 sorbitol Nutrition 0.000 claims description 3
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
229940124530 sulfonamide Drugs 0.000 abstract description 14
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract description 4
IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 abstract description 2
125000004432 carbon atom Chemical group C* 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 abstract 1
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
238000001802 infusion Methods 0.000 description 12
150000003456 sulfonamides Chemical class 0.000 description 12
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
239000003978 infusion fluid Substances 0.000 description 6
235000015097 nutrients Nutrition 0.000 description 6
230000001954 sterilising effect Effects 0.000 description 5
238000004659 sterilization and disinfection Methods 0.000 description 5
-1 sulfonamide salt Chemical class 0.000 description 5
241000282412 Homo Species 0.000 description 4
239000000654 additive Substances 0.000 description 4
241000282472 Canis lupus familiaris Species 0.000 description 3
239000002253 acid Substances 0.000 description 3
239000013543 active substance Substances 0.000 description 3
230000000996 additive effect Effects 0.000 description 3
238000011146 sterile filtration Methods 0.000 description 3
PJVXUVWGSCCGHT-ZPYZYFCMSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;(3s,4r,5r)-1,3,4,5,6-pentahydroxyhexan-2-one Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO PJVXUVWGSCCGHT-ZPYZYFCMSA-N 0.000 description 2
ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
241000700159 Rattus Species 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
JHRWWRDRBPCWTF-OLQVQODUSA-N captafol Chemical compound C1C=CC[C@H]2C(=O)N(SC(Cl)(Cl)C(Cl)Cl)C(=O)[C@H]21 JHRWWRDRBPCWTF-OLQVQODUSA-N 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
244000052769 pathogen Species 0.000 description 2
239000012266 salt solution Substances 0.000 description 2
230000007017 scission Effects 0.000 description 2
159000000000 sodium salts Chemical class 0.000 description 2
229960004793 sucrose Drugs 0.000 description 2
150000008163 sugars Chemical class 0.000 description 2
238000011287 therapeutic dose Methods 0.000 description 2
TZLPBVURAWCOKX-UHFFFAOYSA-N 2-benzyl-4-methoxypyrimidine Chemical compound COC1=CC=NC(CC=2C=CC=CC=2)=N1 TZLPBVURAWCOKX-UHFFFAOYSA-N 0.000 description 1
SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
208000010201 Exanthema Diseases 0.000 description 1
PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
208000003443 Unconsciousness Diseases 0.000 description 1
208000024780 Urticaria Diseases 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
229960004050 aminobenzoic acid Drugs 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
230000037358 bacterial metabolism Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
238000004820 blood count Methods 0.000 description 1
230000005587 bubbling Effects 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000003814 drug Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
201000005884 exanthem Diseases 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
229960000304 folic acid Drugs 0.000 description 1
235000019152 folic acid Nutrition 0.000 description 1
239000011724 folic acid Substances 0.000 description 1
230000037406 food intake Effects 0.000 description 1
230000004927 fusion Effects 0.000 description 1
230000009931 harmful effect Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
229960004903 invert sugar Drugs 0.000 description 1
230000003907 kidney function Effects 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000003908 liver function Effects 0.000 description 1
239000000203 mixture Substances 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
235000021095 non-nutrients Nutrition 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229920000151 polyglycol Polymers 0.000 description 1
239000010695 polyglycol Substances 0.000 description 1
206010037844 rash Diseases 0.000 description 1
238000003307 slaughter Methods 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical class NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000003390 teratogenic effect Effects 0.000 description 1
BKVIYDNLLOSFOA-UHFFFAOYSA-N thallium Chemical compound [Tl] BKVIYDNLLOSFOA-UHFFFAOYSA-N 0.000 description 1
229910052716 thallium Inorganic materials 0.000 description 1
229960001082 trimethoprim Drugs 0.000 description 1
210000001635 urinary tract Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Dermatology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Oil, Petroleum & Natural Gas (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

CS784554A 1977-07-08 1978-07-07 Method of making the well compatible water solution for the intraveous administration CS208479B2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE2731013A DE2731013C2 (de)	1977-07-08	1977-07-08	Verfahren zur Herstellung einer wäßrigen Infusionslösung
AT498477A AT351166B (de)	1977-07-08	1977-07-12	Verfahren zur herstellung einer gut ver- traeglichen, intravenoes zu verabreichenden, waessrigen loesung

Publications (1)

Publication Number	Publication Date
CS208479B2 true CS208479B2 (en)	1981-09-15

Family

ID=25601735

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CS784554A CS208479B2 (en)	1977-07-08	1978-07-07	Method of making the well compatible water solution for the intraveous administration

Country Status (16)

Country	Link
US (1)	US4327084A (de)
JP (1)	JPS5417109A (de)
AT (1)	AT351166B (de)
BE (1)	BE862348A (de)
CH (1)	CH637826A5 (de)
CS (1)	CS208479B2 (de)
DD (1)	DD138506A1 (de)
DE (1)	DE2731013C2 (de)
DK (1)	DK159957C (de)
FI (1)	FI58435C (de)
FR (1)	FR2396550A1 (de)
GB (1)	GB1561562A (de)
IE (1)	IE47876B1 (de)
LU (1)	LU79930A1 (de)
NL (1)	NL179704C (de)
ZA (1)	ZA783677B (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH647412A5 (de) *	1980-03-25	1985-01-31	Hoffmann La Roche	Pharmazeutische praeparate.
FI871447A7 (fi) *	1986-04-07	1987-10-08	Bristol Myers Co	Stabila injicerbara antivomitiva kompositioner.
GB8617482D0 (en) *	1986-07-17	1986-08-28	Geistlich Soehne Ag	Pharmaceutical composition
DE4331147A1 (de) *	1993-09-14	1995-03-16	Nycomed Arzneimittel Gmbh	Intravenös verabreichbare, wäßrige Lösung

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH544053A (de) *	1966-05-09	1973-11-15	Hoffmann La Roche	Verfahren zur Herstellung von Sulfonamidderivaten
SE322866B (de) *	1966-12-15	1970-04-20	Astra Ab
US3637640A (en) *	1970-05-04	1972-01-25	Diagnostic Data Inc	Orgotein stabilized with saccharide process and products
JPS4911403B1 (de) *	1970-12-29	1974-03-16
GB1469521A (en) *	1973-01-05	1977-04-06	Wellcome Found	Antimicrobial preparations

1977
- 1977-07-08 DE DE2731013A patent/DE2731013C2/de not_active Expired
- 1977-07-12 AT AT498477A patent/AT351166B/de not_active IP Right Cessation
- 1977-12-27 BE BE183867A patent/BE862348A/xx not_active IP Right Cessation
1978
- 1978-03-08 GB GB9224/78A patent/GB1561562A/en not_active Expired
- 1978-06-01 DK DK243378A patent/DK159957C/da not_active IP Right Cessation
- 1978-06-09 FI FI781858A patent/FI58435C/fi not_active IP Right Cessation
- 1978-06-15 FR FR7817909A patent/FR2396550A1/fr active Granted
- 1978-06-20 NL NLAANVRAGE7806664,A patent/NL179704C/xx not_active IP Right Cessation
- 1978-06-27 IE IE1283/78A patent/IE47876B1/en not_active IP Right Cessation
- 1978-06-27 ZA ZA00783677A patent/ZA783677B/xx unknown
- 1978-07-06 JP JP8151578A patent/JPS5417109A/ja active Granted
- 1978-07-06 DD DD78206566A patent/DD138506A1/de not_active IP Right Cessation
- 1978-07-06 LU LU79930A patent/LU79930A1/xx unknown
- 1978-07-07 CH CH743778A patent/CH637826A5/de not_active IP Right Cessation
- 1978-07-07 CS CS784554A patent/CS208479B2/cs unknown
1979
- 1979-10-26 US US06/088,651 patent/US4327084A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
JPS5417109A (en)	1979-02-08
DK243378A (da)	1979-01-09
JPS5639285B2 (de)	1981-09-11
NL179704B (nl)	1986-06-02
DE2731013A1 (de)	1979-01-11
FI58435C (fi)	1981-02-10
GB1561562A (en)	1980-02-27
DE2731013C2 (de)	1982-07-15
DD138506A1 (de)	1979-11-07
DK159957B (da)	1991-01-07
IE47876B1 (en)	1984-07-11
NL7806664A (nl)	1979-01-10
ATA498477A (de)	1978-12-15
BE862348A (fr)	1978-06-27
LU79930A1 (de)	1978-12-07
CH637826A5 (de)	1983-08-31
FI781858A7 (fi)	1979-01-09
FR2396550B1 (de)	1980-06-13
IE781283L (en)	1979-01-08
NL179704C (nl)	1986-11-03
AT351166B (de)	1979-07-10
US4327084A (en)	1982-04-27
ZA783677B (en)	1979-07-25
FR2396550A1 (fr)	1979-02-02
DK159957C (da)	1991-05-27
FI58435B (fi)	1980-10-31

Publication	Publication Date	Title
CA2468916C (en)	2009-01-20	A stable oxaliplatin solution formulation
US5589491A (en)	1996-12-31	Injection and injection kit containing omeprazole and its analogs
RU2260429C2 (ru)	2005-09-20	Составы моксифлоксацина, содержащие поваренную соль
EA013846B1 (ru)	2010-08-30	Фармацевтическая композиция, содержащая лактат, и ее применение
KR910005885B1 (ko)	1991-08-06	염화리소짐 및 글리치르히진산 디칼륨 함유 수용액제제
EP1641460A2 (de)	2006-04-05	Stabile pharmazeutische zusammensetzungen von 5,10-methylentetrahydrofolat
CS208479B2 (en)	1981-09-15	Method of making the well compatible water solution for the intraveous administration
EP1259244B1 (de)	2003-08-27	Tierärztliche zusammensetzungen zur behandlung von parasiterkrankungen
US4696814A (en)	1987-09-29	Parenteral phenytoin compositions
FI68970B (fi)	1985-08-30	Foerfarande foer framstaellning av en ny medicinskt anvaendbarhemin-foerening
NL194430C (nl)	2002-04-04	Niet-injecteerbaar farmaceutisch preparaat met anti-kankerwerking.
JP3877807B2 (ja)	2007-02-07	口内炎治療・予防剤
JP2001500872A (ja)	2001-01-23	ジチオエーテルを用いたカルボプラチンの毒減少効果
CN110721152B (zh)	2022-01-14	一种治疗动物皮肤寄生虫、真菌感染的缓释组合物
HU185415B (en)	1985-02-28	Process for producing aquous solution of water soluble sulfanomide salt, sulfonamide potenciator, based on aldehydes, and derivatives
EP0302097B1 (de)	1993-04-28	Pharmazeutische zusammensetzungen zur behandlung der verstopfung der luftwege
KR20210144811A (ko)	2021-11-30	벤조아제핀 화합물-함유 제약 조성물
DK143997B (da)	1981-11-16	Fremgangsmaade til stabilisering af sulfonamid/potentiatoroploesninger
RU2798118C1 (ru)	2023-06-15	Способ получения инъекционной фармацевтической композиции для животных на основе метилурацила (диоксометилтетрагидропиримидина)
KR20010027403A (ko)	2001-04-06	구연산칼륨을 주제로 한 요로결석치료제의 제조방법
RU2181051C1 (ru)	2002-04-10	Способ получения инъекционного средства на основе вещества с р-витаминной активностью
EP3678498A1 (de)	2020-07-15	Zusammensetzung zur calciumergänzung
EP0082667A1 (de)	1983-06-29	Pharmazeutische Zusammensetzungen
KR100486089B1 (ko)	2005-04-29	암프롤륨, 설파퀴녹살린, 및 에토파베이트를 함유하는액상제제의 제조방법
US7645765B2 (en)	2010-01-12	Use of moxaverin for treating erectile dysfunction, forms of dementia or diseases associated to an arteriosclerotic occlusion